AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. CAI
  4. [Form 4] Caris Life Sciences, Inc. Insider Trading Activity

[Form 4] Caris Life Sciences, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

David Baxley Spetzler, President of Caris Life Sciences (CAI), filed a Form 4 reporting a transaction dated 08/11/2025 in the issuer's common stock. The filing records 63,509 shares and a per-share price of $29.75, and shows 460,377 shares beneficially owned following the reported transaction, held directly. The form was signed by an attorney-in-fact on 08/13/2025.

David Baxley Spetzler, presidente di Caris Life Sciences (CAI), ha presentato un Modulo 4 che segnala una transazione sulle azioni ordinarie dell'emittente datata 08/11/2025. Il documento riporta 63,509 azioni a un prezzo per azione di $29.75 e indica che, a seguito dell'operazione, risultano beneficiariamente detenute 460,377 azioni, possedute direttamente. Il modulo 猫 stato firmato da un procuratore il 08/13/2025.

David Baxley Spetzler, presidente de Caris Life Sciences (CAI), present贸 un Formulario 4 que informa de una operaci贸n sobre las acciones ordinarias del emisor con fecha 08/11/2025. La presentaci贸n registra 63,509 acciones a un precio por acci贸n de $29.75, y muestra que tras la operaci贸n posee beneficiariamente 460,377 acciones, mantenidas directamente. El formulario fue firmado por un apoderado el 08/13/2025.

David Baxley Spetzler電� Caris Life Sciences (CAI) 靷灔鞙茧靹� 氚滍枆鞚胳潣 氤错喌欤检棎 雽�頃� 瓯半灅毳� 08/11/2025鞚检瀽搿� 氤搓碃頃� Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 鞁犼碃靹滌棎電� 欤茧嫻 臧�瓴� $29.75搿� 63,509欤缄皜 旮半霅橃柎 鞛堨溂氅�, 鞁犼碃霅� 瓯半灅 鞚错泟 460,377欤茧ゼ 歆侅为 氤挫湢頃橁碃 鞛堨潓鞚� 雮橅儉雰呺媹雼�. 頃措嫻 鞏戩嫕鞚� 08/13/2025鞐� 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.

David Baxley Spetzler, pr茅sident de Caris Life Sciences (CAI), a d茅pos茅 un formulaire 4 d茅clarant une transaction sur les actions ordinaires de l'茅metteur en date du 08/11/2025. Le d茅p么t mentionne 63,509 actions au prix unitaire de $29.75 et indique qu'脿 la suite de la transaction, 460,377 actions sont d茅tenues 脿 titre b茅n茅ficiaire, d茅tenues directement. Le formulaire a 茅t茅 sign茅 par un mandataire le 08/13/2025.

David Baxley Spetzler, Pr盲sident von Caris Life Sciences (CAI), reichte ein Formular 4 ein, das eine Transaktion mit den Stammaktien des Emittenten zum Datum 08/11/2025 meldet. Die Einreichung verzeichnet 63,509 Aktien zu einem Preis von $29.75 je Aktie und zeigt, dass nach der gemeldeten Transaktion 460,377 Aktien beg眉nstigt gehalten werden, und zwar direkt. Das Formular wurde am 08/13/2025 von einem Bevollm盲chtigten unterschrieben.

Positive
  • Full disclosure of key fields: transaction date, share amount, per-share price, and post-transaction beneficial ownership are provided
  • Reporting person identified by role (President) and filing bears a dated signature by an attorney-in-fact
Negative
  • Reported disposal of 63,509 shares (the filing shows the share amount and associated indicator)
  • Transaction code 'F' is present but the filing contains no additional explanation or context for that code

Insights

Routine insider transaction disclosed: 63,509 shares at $29.75; post-transaction direct holdings 460,377 shares.

The Form 4 shows the issuer's President, David Baxley Spetzler, reported a transaction in common stock dated 08/11/2025. The filing lists 63,509 shares and a price of $29.75, with 460,377 shares reported as beneficially owned after the transaction and held directly. The disclosure is concise and includes a dated signature by an attorney-in-fact on 08/13/2025. The filing does not provide additional narrative context or explanation for the transaction code shown.

Disclosure appears complete for required Form 4 fields; no explanatory context provided for the transaction code.

The report identifies the reporting person as the company's President and provides the transaction date, share amount, per-share price, and post-transaction beneficial ownership, all standard elements for Section 16 reporting. The form is executed by an attorney-in-fact. The filing does not include descriptive information about the purpose or circumstances of the transaction beyond the tabulated fields and the transaction code, which remains unexplained in the document.

David Baxley Spetzler, presidente di Caris Life Sciences (CAI), ha presentato un Modulo 4 che segnala una transazione sulle azioni ordinarie dell'emittente datata 08/11/2025. Il documento riporta 63,509 azioni a un prezzo per azione di $29.75 e indica che, a seguito dell'operazione, risultano beneficiariamente detenute 460,377 azioni, possedute direttamente. Il modulo 猫 stato firmato da un procuratore il 08/13/2025.

David Baxley Spetzler, presidente de Caris Life Sciences (CAI), present贸 un Formulario 4 que informa de una operaci贸n sobre las acciones ordinarias del emisor con fecha 08/11/2025. La presentaci贸n registra 63,509 acciones a un precio por acci贸n de $29.75, y muestra que tras la operaci贸n posee beneficiariamente 460,377 acciones, mantenidas directamente. El formulario fue firmado por un apoderado el 08/13/2025.

David Baxley Spetzler電� Caris Life Sciences (CAI) 靷灔鞙茧靹� 氚滍枆鞚胳潣 氤错喌欤检棎 雽�頃� 瓯半灅毳� 08/11/2025鞚检瀽搿� 氤搓碃頃� Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 鞁犼碃靹滌棎電� 欤茧嫻 臧�瓴� $29.75搿� 63,509欤缄皜 旮半霅橃柎 鞛堨溂氅�, 鞁犼碃霅� 瓯半灅 鞚错泟 460,377欤茧ゼ 歆侅为 氤挫湢頃橁碃 鞛堨潓鞚� 雮橅儉雰呺媹雼�. 頃措嫻 鞏戩嫕鞚� 08/13/2025鞐� 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.

David Baxley Spetzler, pr茅sident de Caris Life Sciences (CAI), a d茅pos茅 un formulaire 4 d茅clarant une transaction sur les actions ordinaires de l'茅metteur en date du 08/11/2025. Le d茅p么t mentionne 63,509 actions au prix unitaire de $29.75 et indique qu'脿 la suite de la transaction, 460,377 actions sont d茅tenues 脿 titre b茅n茅ficiaire, d茅tenues directement. Le formulaire a 茅t茅 sign茅 par un mandataire le 08/13/2025.

David Baxley Spetzler, Pr盲sident von Caris Life Sciences (CAI), reichte ein Formular 4 ein, das eine Transaktion mit den Stammaktien des Emittenten zum Datum 08/11/2025 meldet. Die Einreichung verzeichnet 63,509 Aktien zu einem Preis von $29.75 je Aktie und zeigt, dass nach der gemeldeten Transaktion 460,377 Aktien beg眉nstigt gehalten werden, und zwar direkt. Das Formular wurde am 08/13/2025 von einem Bevollm盲chtigten unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Spetzler David Baxley
(Last) (First) (Middle)
C/O CARIS LIFE SCIENCES, INC.
750 W. JOHN CARPENTER FREEWAY, SUITE 800
(Street)
IRVING TX 75039
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President
3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/11/2025 F 63,509 D $29.75 460,377 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ J. Russel Denton, Attorney-in-Fact for David Baxley Spetzler 08/13/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

Who filed the Form 4 for Caris Life Sciences (CAI)?

David Baxley Spetzler, identified as President, filed the Form 4 (signed by an attorney-in-fact on 08/13/2025).

What transaction is reported on the CAI Form 4?

A transaction dated 08/11/2025 in CAI common stock reporting 63,509 shares and a per-share price of $29.75.

How many CAI shares does the reporting person own after the transaction?

The filing reports 460,377 shares beneficially owned following the reported transaction, held directly.

Does the Form 4 explain the transaction code used?

The filing shows transaction code F but does not provide an explanatory note or narrative for the code.

When was the Form 4 signed?

The signature block shows 08/13/2025 with J. Russel Denton signing as attorney-in-fact for the reporting person.
Stock CAI logo
CAI Intl

NASDAQ:CAI

CAI Rankings

#955 Ranked by Market Cap
N/A Ranked by Dividends

CAI Latest News

Aug 15, 2025
Caris Life Sciences Demonstrates Scientific Rigor with Clinical Validation of FDA-Approved MI Cancer Seek庐
Aug 13, 2025
New Study from Caris Life Sciences Validates Optimal Sequencing in Informing Therapy Choices for Breast Cancer Subgroups
Aug 12, 2025
Caris Life Sciences Reports Second Quarter 2025 Financial Results
Aug 6, 2025
Caris Life Sciences Publishes Study Showing AI Signature-positive Breast Cancer Patients Live Almost Twice as Long as AI-negative Patients When Treated with a Checkpoint Inhibitor
Aug 5, 2025
Caris Life Sciences Publishes Study Showing its Multi-Layer AI-Based Tissue of Origin Predictions are Best-in-Class and Identify when Patients have been Misdiagnosed

CAI Latest SEC Filings

Aug 13, 2025
[Form 4] Caris Life Sciences, Inc. Insider Trading Activity
Aug 13, 2025
[Form 4] Caris Life Sciences, Inc. Insider Trading Activity
Aug 13, 2025
[SCHEDULE 13G] Caris Life Sciences, Inc. SEC Filing
Aug 12, 2025
[10-Q] Caris Life Sciences, Inc. Quarterly Earnings Report
Aug 12, 2025
[8-K] Caris Life Sciences, Inc. Reports Material Event

CAI Stock Data

9.02B
126.74M
49.68%
19.33%
0.56%
Biotechnology
Services-medical Laboratories
United States
IRVING